The mission of the Alzheimer’s Association® Business Consortium (AABC) is to advance Alzheimer’s disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer’s research and the goals of its member organizations. They provide leadership and direction to the groups’ areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Jacob Donoghue (jake@beacon.bio), co-chair, Dr. Ornit Chiba-Falek (ornit.chibafalek@clairigene.com), co-chair, or Dr. Christopher Weber (cweber@alz.org), facilitator.

Welcome to our New Members

AABC is growing! Welcome to:

- **Lenny Kristal, Paul Slowey, Rory Stear, Mike O’Donnell**
  - **Baseline Bioscience** has patented technology which will analyze saliva for a broad range of medical conditions, such as Alzheimer’s disease, and that analysis is almost immediate and is non-invasive, resulting in no patient reluctance to undergo the analysis. Saliva is a proven carrier of analytes, such as proteins, that are known to be indicative of various medical conditions. The purpose of the device is to identify those analytes for chosen significant medical conditions and to develop accurate, rapid, easy-to-use devices to assess for those analytes. This means that more patients will get assessed for their potential medical conditions sooner, and they will, therefore, be more likely to start treatment sooner. In some cases, earlier diagnosis and treatment can be more convenient for the patient; in other cases, earlier diagnosis and treatment can be absolutely critical in the life of the patient.

- **Neil Mathur, Brian Zweben, Jet Sethi**
  - **Innovative Precision Health (IPH)** is a healthcare analytics company that delivers multi-dimensional patient performance data and comparative efficacy metrics to optimize the continuum of patient care. By collecting and analyzing population health data and harnessing the power of machine learning algorithms, IPH can provide actionable insights that help improve patient outcomes. Our main product is a data aggregation platform that provides clinicians with organized patient data from multiple sources. Our technology has the potential to better predict patient outcomes, lower costs, and optimize treatment pathways.

- **Ziv Yekuteli**
  - **Montfort** offers a quantitative neurological assessment platform that provides Motor, Cognitive & Affective digital-markers. Montfort turns a regular smartphone into a portable lab, reducing test time and costs, allowing the evaluation to be taken anywhere and anytime, including in the patient’s natural environment. The tests are based upon existing and validated medical standards. Montfort’s team specializes in brain-science, big data and data analytics. Montfort has run numerous clinical trials, as the sponsor for internal validation, as a medical device provider of digital markers for pharma and medical devices companies, and as a CRO.

- **Luiz Augusto de Paula, Shannon Campbell**
  - **Optina Diagnostics** focuses on changing mindsets when it comes to Brain Health by using the retina, the only part of the central nervous system with direct visual access, as a representation of the brain. Our innovative approach challenges the status quo and offers a non-invasive, simple, and readily accessible eye test to support the detection and monitoring of pathologies underlying cognitive decline. The technology was granted Breakthrough Device Designation by the FDA in 2019, and Optina is actively enrolling participants in its pivotal REPRAISE Study (NCT05107882). Optina is supported by ADDF and was the winner of the Frost & Sullivan North American Technology Innovation Leadership Award in 2022.
» **Mythra Varun Nemallapudi**, PraanaTech is an early-stage startup building next generation radiation imaging technology for affordable early diagnosis of Alzheimer’s. Their flagship product, FlexPET is the world’s first compact and truly portable PET device which has been designed to perform organ specific, region-of-interest imaging, making it adaptable to a wide range of applications including Cancer diagnosis. PraanaTech’s vision is to provide continuous monitoring to neurologists across the US that makes treatment effective. With a team of experienced scientists, researchers and engineers from some of the world’s top institutions such as CERN, Academia Sinica and University of Chicago IL, this high-resolution PET was developed with an objective to change the way patients are currently imaged. With a fully developed prototype in hand and a high potential emerging market, PraanaTech is now actively seeking business and clinical partnerships to take their technology into the world.

» **Cynthia Benjamin, Deborah Barnes**

Together Senior Health delivers evidence-based, enjoyable, online programs that combine multiple lifestyle elements and reduce the impact, cost and burden associated with cognitive decline. Our research-based programs are designed specifically to appeal to and benefit this audience, combining neuroscience and compassion and delivering solid ROI outcomes to our risk-based enterprise customers. We are deeply committed to continuing to prove the efficacy of our approach and helping older adults impacted by memory loss to live their best lives today.

---

**AAIC® 2024**

Save the date for the abstract submission opening for the Alzheimer’s Association International Conference® 2024 (AAIC®), July 28-Aug.1, 2024 in Philadelphia, USA, and online.

Submit an abstract or session proposal for the opportunity to spotlight your research at the largest international meeting dedicated to advancing dementia science. Don’t miss the chance to feature your work among more than 4,500 poster presentations and over 750 podium sessions. Opportunities to present in person and online are available.

Are you an ISTAART member? Join the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) to receive exclusive benefits at AAIC 2024 and year-round. Member benefits at AAIC include extended abstract submission deadlines, no-cost virtual registration and discounted in-person registration fees, and access to key events such as ISTAART Professional Interest Area (PIA) Day and the ISTAART Educational Series.

**Social Media**

Follow our [LinkedIn](https://www.linkedin.com) page! We look forward to using the page to foster partnerships and communications.

Join our Slack channel! We launched a Slack channel in 2022 to encourage open and direct communications between all members. If interested in joining, please reach out to Ashley Hansen ([ahansen@alz.org](mailto:ahansen@alz.org)).

**Spread the Word**

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at ([ahansen@alz.org](mailto:ahansen@alz.org)).